In March 2023, Cygnus received another round of Series C+ financing of hundreds of millions of RMB, led by Source Capital, and followed by Jianxin Equity, Yizhuang State Investment, Fangzhenghesheng, and Hetang Venture Capital. This is another round of Series C+ financing following the completion of the investment led by State Transfer Fund in August 2022.

After the completion of this round of financing, Cygnus will continue to strengthen R&D, build up the team's sustainable original innovation capability, accelerate the launch of medium and large throughput sequencing platforms; promote the filing of Class III medical device registration certificates; strengthen marketing and commercialization capabilities, and actively explore and expand broader commercial application scenarios with industry chain partners.

Founded in 2015, Cygnu is a domestic NGS gene sequencer that adopts the original technology route. Relying on the company's core technology, Cygnu can improve sequencing accuracy to Q40 and significantly reduce sequencing cost. The company's desktop S100 sequencer has received widespread recognition from users across a wide range of applications.